EGFR and neoplasm: We showed that DAs in other drivers, such as CDKN2A, EGFR and TP53, are associated with fairly distinct sets of DEMs and DMGs with distinct contributions toward tumor phenotype, as apparent from the enriched GO terms and pathways.